MedTrace Logo

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-07-29

Study results available
· View outcomes & findings →

Summary

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

Conditions

Interventions

DRUG

Cannabidiol

Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)

Sponsors & Collaborators

Principal Investigators

  • Jon E Grant, MD, JD, MPH · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2025-11-01
Completion
2025-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04978428 on ClinicalTrials.gov